Literature DB >> 12183254

Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia.

Roman S Kozlov1, Tatiana M Bogdanovitch, Peter C Appelbaum, Lois Ednie, Leonid S Stratchounski, Michael R Jacobs, Bülent Bozdogan.   

Abstract

The susceptibilities of 468 recent Russian clinical Streptococcus pneumoniae isolates and 600 Streptococcus pyogenes isolates, from 14 centers in Russia, to telithromycin, erythromycin, azithromycin, clarithromycin, clindamycin, levofloxacin, quinupristin-dalfopristin, and penicillin G were tested. Penicillin-nonsusceptible S. pneumoniae strains were rare except in Siberia, where their prevalence rate was 13.5%: most were penicillin intermediate, but for three strains (two from Smolensk and one from Novosibirsk) the MICs of penicillin G were 4 or 8 micro g/ml. Overall, 2.5% of S. pneumoniae isolates were resistant to erythromycin. Efflux was the prevalent resistance mechanism (five strains; 41.7%), followed by ribosomal methylation encoded by constitutive erm(B), which was found in four isolates. Ribosomal mutation was the mechanism of macrolide resistance in three isolates; one erythromycin-resistant S. pneumoniae isolate had an A2059G mutation in 23S rRNA, and two isolates had substitution of GTG by TPS at positions 69 to 71 in ribosomal protein L4. All S. pyogenes isolates were susceptible to penicillin, and 11% were erythromycin resistant. Ribosomal methylation was the most common resistance mechanism for S. pyogenes (89.4%). These methylases were encoded by erm(A) [subclass erm(TR)] genes, and their expression was inducible in 96.6% of isolates. The rest of the erythromycin-resistant Russian S. pyogenes isolates (7.6%) had an efflux resistance mechanism. Telithromycin was active against 100% of pneumococci and 99.2% of S. pyogenes, and levofloxacin and quinupristin-dalfopristin were active against all isolates of both species.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183254      PMCID: PMC127395          DOI: 10.1128/AAC.46.9.2963-2968.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Susceptibility of group A beta-hemolytic streptococci to thirteen antibiotics: examination of 301 strains isolated in the United States between 1994 and 1997.

Authors:  E L Kaplan; D R Johnson; M C Del Rosario; D L Horn
Journal:  Pediatr Infect Dis J       Date:  1999-12       Impact factor: 2.129

2.  Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.

Authors:  T A Davies; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

3.  In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.

Authors:  T A Davies; G A Pankuch; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods.

Authors:  E L Fasola; S Bajaksouzian; P C Appelbaum; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.

Authors:  M R Jacobs; S Bajaksouzian; A Zilles; G Lin; G A Pankuch; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.

Authors:  G A Pankuch; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California.

Authors:  M K York; L Gibbs; F Perdreau-Remington; G F Brooks
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

8.  Detection of erythromycin-resistant determinants by PCR.

Authors:  J Sutcliffe; T Grebe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

9.  Resistance of Streptococcus pyogenes to erythromycin and related antibiotics in Italy. The Italian Surveillance Group for Antimicrobial Resistance.

Authors:  G Cornaglia; M Ligozzi; A Mazzariol; L Masala; G Lo Cascio; G Orefici; R Fontana
Journal:  Clin Infect Dis       Date:  1998-08       Impact factor: 9.079

10.  Erythromycin resistance of Streptococcus pyogenes in Madrid.

Authors:  B Orden; E Perez-Trallero; M Montes; R Martínez
Journal:  Pediatr Infect Dis J       Date:  1998-06       Impact factor: 2.129

View more
  10 in total

1.  Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002.

Authors:  M Rantala; S Huikko; P Huovinen; J Jalava
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

2.  Streptococcus pneumoniae isolates resistant to telithromycin.

Authors:  M Rantala; M Haanperä-Heikkinen; M Lindgren; H Seppälä; P Huovinen; J Jalava
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

3.  Macrolones Are a Novel Class of Macrolide Antibiotics Active against Key Resistant Respiratory Pathogens In Vitro and In Vivo.

Authors:  Hana Čipčić Paljetak; Donatella Verbanac; Jasna Padovan; Miroslava Dominis-Kramarić; Željko Kelnerić; Mihaela Perić; Mihailo Banjanac; Gabrijela Ergović; Nerrisa Simon; John Broskey; David J Holmes; Vesna Eraković Haber
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

4.  Antipneumococcal activities of two novel macrolides, GW 773546 and GW 708408, compared with those of erythromycin, azithromycin, clarithromycin, clindamycin, and telithromycin.

Authors:  Vlatka Matic; Klaudia Kosowska; Bulent Bozdogan; Linda M Kelly; Kathy Smith; Lois M Ednie; Gengrong Lin; Kim L Credito; Catherine L Clark; Pamela McGhee; Glenn A Pankuch; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

5.  Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003.

Authors:  Ralf René Reinert; Susanne Reinert; Mark van der Linden; Murat Y Cil; Adnan Al-Lahham; Peter Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  In vitro activity of telithromycin against macrolide-susceptible and macrolide-resistant pharyngeal isolates of group A streptococci in the United States.

Authors:  Michael Green; Coburn Allen; John Bradley; Barry Dashefsky; Janet R Gilsdorf; Mario J Marcon; Gordon E Schutze; Clay Smith; Emmanuel Walter; Judith M Martin; Kathryn A Edwards; Karen A Barbadora; Renee M Rumbaugh; Ellen R Wald
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA.

Authors:  Guy W Novotny; Lene Jakobsen; Niels M Andersen; Jacob Poehlsgaard; Stephen Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Activities of a new oral streptogramin, XRP 2868, compared to those of other agents against Streptococcus pneumoniae and haemophilus species.

Authors:  Glenn A Pankuch; Linda M Kelly; Gengrong Lin; Andre Bryskier; Catherine Couturier; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 Data.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Chun-Ming Lee; Wen-Kuei Huang; Tsu-Lan Wu; Jen-Hsien Wan; Dine Yang; Jainn-Ming Shyr; Yin-Ching Chuang; Jing-Jou Yan; Jang-Jih Lu; Jiunn-Jong Wu; Wen-Chien Ko; Feng-Yee Chang; Yi-Chueh Yang; Yeu-Jun Lau; Yung-Ching Liu; Hsieh-Shong Leu; Cheng-Yi Liu; Kwen-Tay Luh
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Ribosomal mutations conferring resistance to macrolides in Streptococcus pneumoniae clinical strains isolated in Germany.

Authors:  Ralf René Reinert; Angela Wild; Peter Appelbaum; Rudolf Lütticken; Murat Yücel Cil; Adnan Al-Lahham
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.